InflaRx (IFRX) AI Stock Analysis

• Market Cap: $93.99M
• Dividend Yield: N/A
• Average Volume (3M): 574.11K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.58
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 74
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.24
• Shares Outstanding: 67,133,270
• 10 Day Avg. Volume: 649,163
• 30 Day Avg. Volume: 574,111
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -0.02
• Enterprise Value/Revenue: -13.00
• Enterprise Value/Gross Profit: 0.42
• Enterprise Value/Ebitda: 0.05
• 1Y Price Target: $4.00
• Price Target Upside: 185.71% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 44 Neutral
• Price Target: $1.50 ▲(7.14% Upside)

InflaRx's overall stock score is primarily impacted by its weak financial performance, characterized by ongoing losses and cash flow challenges. While technical indicators show some positive short-term trends, the lack of profitability and valuation concerns weigh heavily on the score.

Positive Factors

Product Development Focus

InflaRx's focus on innovative therapies for inflammatory diseases positions it well in a niche market, potentially leading to breakthrough treatments and partnerships.

Strategic Partnerships

Strategic partnerships provide funding and development opportunities, enhancing InflaRx's ability to bring products to market and expand its reach.

Nasdaq Compliance

Regaining Nasdaq compliance stabilizes InflaRx's market position and reassures investors, supporting long-term market presence and potential capital access.

Negative Factors

Financial Challenges

Ongoing financial challenges limit InflaRx's ability to invest in growth and innovation, potentially hindering its competitive position and long-term viability.

Negative Cash Flow

Negative cash flow indicates cash burn issues, which can strain resources and limit InflaRx's ability to sustain operations without additional funding.

High R&D Costs

High R&D costs contribute to financial strain, impacting profitability and necessitating careful management to ensure sustainable investment in product development.

InflaRx Business Overview & Revenue Model

Company Description

InflaRx (IFRX) is a biopharmaceutical company focused on developing innovative therapies for inflammatory diseases. The company specializes in monoclonal antibodies targeting the complement system, which plays a critical role in immune response and inflammation. InflaRx's lead product candidate, IFX-1, is designed to treat conditions such as hidradenitis suppurativa and other severe inflammatory diseases, positioning the company at the intersection of immunology and biotherapeutics.

How the Company Makes Money

InflaRx generates revenue primarily through the development and commercialization of its therapeutic candidates. The company may earn income through various channels, including grants, collaborations, and partnerships with larger pharmaceutical companies, which often provide funding in exchange for rights to market or co-develop its products. Additionally, successful clinical trials can lead to milestone payments from partners, while eventual product sales, if approved, will become a significant revenue stream. The company's strategic focus on addressing unmet medical needs in inflammatory diseases also increases its potential for attracting investment and partnerships, driving its earnings.

InflaRx Financial Statement Overview

Summary

InflaRx's financials reflect significant operational and financial challenges. The company is struggling with profitability and cash flow management, evident from negative margins and consistent cash outflows. While the balance sheet shows limited leverage, negative returns and persistent losses are concerning for future financial stability.

Income Statement

InflaRx's income statement shows significant challenges in profitability and revenue growth. The company has been operating at a loss with negative net income and gross profit margins. Although total revenue increased from 2023 to 2024, the net profit margin remains negative, reflecting continued financial strain.

Balance Sheet

The balance sheet highlights high equity levels relative to debt, but the company has been operating with net debt positions, suggesting better liquidity management. However, the return on equity is negative due to persistent net losses, pointing to concerns in generating returns for shareholders.

Cash Flow

InflaRx's cash flow statement indicates consistent negative operating cash flow and free cash flow, suggesting ongoing cash burn issues. The free cash flow to net income ratio is poor, pointing to challenges in converting earnings into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	162.83K	165.79K	63.09K	0.00	0.00	0.00
Gross Profit	-4.99M	-3.15M	-469.17K	-585.85K	-696.14K	-664.03K
EBITDA	-44.73M	-45.55M	-42.06M	-31.29M	-46.90M	-32.47M
Net Income	-45.29M	-46.06M	-42.67M	-27.04M	-45.65M	-34.01M
Balance Sheet
Total Assets	73.44M	76.02M	120.21M	102.40M	125.14M	88.22M
Cash, Cash Equivalents and Short-Term Investments	48.00M	52.84M	90.27M	81.81M	83.41M	81.13M
Total Debt	599.11K	805.09K	1.12M	1.36M	1.43M	559.04K
Total Liabilities	16.40M	14.60M	17.63M	14.05M	19.86M	10.35M
Stockholders Equity	57.04M	61.42M	102.58M	88.35M	105.28M	77.86M
Cash Flow
Free Cash Flow	-43.17M	-48.60M	-37.89M	-33.91M	-39.97M	-36.62M
Operating Cash Flow	-43.12M	-48.56M	-37.81M	-33.74M	-39.94M	-36.53M
Investing Cash Flow	12.17M	52.36M	-17.70M	19.36M	-25.95M	21.36M
Financing Cash Flow	27.49M	386.45K	52.99M	1.94M	61.58M	9.17M

InflaRx Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.40
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IFRX, the sentiment is Positive. The current price of 1.4 is above the 20-day moving average (MA) of 1.35, above the 50-day MA of 1.30, and above the 200-day MA of 1.34, indicating a bullish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 54.21 is Neutral, neither overbought nor oversold. The STOCH value of 54.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IFRX.

InflaRx Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ATRA	52 Neutral	$101.76M	-34.09	―	―	202.41%	98.99%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CLNN	49 Neutral	$83.98M	-3.21	―	―	-35.29%	45.18%
ANIX	49 Neutral	$136.28M	-12.01	-57.94%	―	―	11.78%
ORMP	47 Neutral	$98.00M	-3.93	-14.57%	―	―	-217.26%
IFRX	44 Neutral	$93.99M	-1.34	―	―	―	―
ABOS	36 Underperform	$133.87M	-0.98	-75.71%	―	―	-103.31%

InflaRx Corporate Events

InflaRx Regains Nasdaq Compliance with Share Price Recovery

On September 11, 2025, InflaRx N.V. announced it regained compliance with Nasdaq’s minimum bid price requirement after its share price met the $1.00 threshold for 10 consecutive business days. This development closes a compliance issue that began on July 11, 2025, when the company was notified of its non-compliance due to a prolonged period of low share prices. Regaining compliance is a positive step for InflaRx, potentially stabilizing its market position and reassuring stakeholders.

InflaRx Reports Significant Losses in H1 2025 Financials

InflaRx N.V. released its unaudited condensed consolidated financial statements for the six months ending June 30, 2025, reporting a significant loss. The company experienced a gross loss of €2.37 million and an operating loss of €25.92 million, despite generating €39,432 in revenue. The financial results highlight ongoing challenges in managing costs, particularly in research and development, which amounted to €14.22 million. The announcement underscores the financial pressures faced by InflaRx as it continues to invest heavily in its pipeline, impacting its market positioning and stakeholder confidence.